Hemorrhage Clinical Trial
Official title:
Comparison of Compensatory Reserve Index to Changes in Stroke Volume and Intravascular Volume
The purpose of this study is to demonstrate the correlation of the Compensatory Reserve Index (CRI) numeric and graphical trend readings to intravascular volume changes as compared to graded blood loss (removal of 20% of estimated total blood volume in ~333 mL aliquots) and to stroke volume as measured by the Nexfin monitor during the same graded blood removal period. Enrollment includes both men and women.
Sequential Blood Loss: Blood loss will be simulated by withdrawal of 20% of estimated total
blood volume. Estimated total blood volume for men = 75 mL/kg and for women = 65 mL/kg. The
calculated target withdrawal volume is also consistent with an allowable estimated blood
loss equation assuming a starting hematocrit (hct) of approximately 45% in males and 40% in
females, where the expected drop in hct for this volume withdrawn is 7 percentage points in
males and 6 percentage points in females. An actual drop in hct may not be observed in this
study due to the relatively expedient removal of blood and no simultaneous administration of
fluids (i.e., no "hemodilution" with crystalloid). Blood will be removed in aliquots up to
~333 mL. For safety, men will have no more than 4 units of blood removed (1,333 mL) and
women will have no more than 3 units of blood removed (1,000 mL).
The blood will be withdrawn via the venous catheter and we anticipate that it will take
15-20 min for each stage of blood withdrawal to occur. A total of 3 aliquots will be
withdrawn over approximately sixty minutes in women and 4 aliquots withdrawn over 80 minutes
in men. The blood will be stored using preservatives and anticoagulation procedures similar
to those used for perioperative hemodilution and/or intraoperative cell saver. The blood
will remain in the study room until it is re-infused. We will use standard
"auto-transfusion" blood collection equipment identical to that used in the ORs for
perioperative hemodilution techniques. The blood will be drained by gravity from an
indwelling vascular catheter into anti-coagulant preservative solution using tubing and bags
systems provided by the autologous transfusion team that we routinely work with in the ORs.
For the first several studies we will schedule them at a time when auto-transfusion OR
personnel can be present and after that the anesthesiologists will be directly involved in
drawing the blood, subsequent handling and reinfusion. The blood will never leave the
autologous transfusion bag and a closed system will be used. The blood will be held at room
temp with gentle agitation for ~60-80 minutes and then re-infused over 60-80 minutes via a
large bore IV; monitoring will continue during reinfusion. Following completion of the
reinfusion subjects will de-instrumented and observed in the physiology lab for two hours.
;
Observational Model: Case-Only, Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02815670 -
Reversal Dabigatran Anticoagulant Effect With Idarucizumab
|
Phase 3 | |
| Completed |
NCT04588350 -
Clinical Investigation Evaluating a New Autotransfusion Device in Cardiac Surgery
|
N/A | |
| Recruiting |
NCT02972385 -
Pharmacogenomics of Warfarin in Hispanics and Latinos
|
||
| Completed |
NCT02554006 -
Predischarge Bundle to Minimize Negative Impact on Quality of Life of Nuisance Bleedings
|
N/A | |
| Completed |
NCT02569606 -
Transfusion and Coagulation Management in Trauma Patients After the Introduction of a Coagulation Algorithm
|
||
| Recruiting |
NCT02446730 -
Efficacy and Safety of BiomatrixTM Stent and 5mg-Maintenance Dose of Prasugrel in Patients With Acute Coronary Syndrome
|
Phase 4 | |
| Completed |
NCT01955720 -
Safety, Tolerability, PK and PD of BI 655075 and Establishment of BI 655075 Dose(s) Effective to Reverse Prolongation of Blood Coagulation Time by Dabigatran
|
Phase 1 | |
| Completed |
NCT01935427 -
Comparison of Compensatory Reserve Index to Intravascular Volume Change and Stroke Volume
|
N/A | |
| Recruiting |
NCT01709786 -
Non-Invasive Hemoglobin Monitoring in Patients With Hemorrhage
|
N/A | |
| Completed |
NCT01210417 -
Trauma Heart to Arm Time
|
N/A | |
| Completed |
NCT01136590 -
Multicenter, Randomized Placebo-controlled Clinical Trial to Evaluate the Effect of Perioperative Use of Tranexamic Acid on Transfusion Requirements and Surgical Bleeding in Major Spine Surgery
|
Phase 4 | |
| Completed |
NCT01191554 -
Dose-ranging Study of Tranexamic Acid in Valve Surgery
|
N/A | |
| Completed |
NCT01085006 -
The Effect of Tranexamic Acid on Postpartum Hemorrhage During and After Cesarean Delivery
|
Phase 1/Phase 2 | |
| Completed |
NCT00700141 -
Non-Interventional Study About Treatment of Hemorrhages in Thyroid Surgery With TachoSil®
|
N/A | |
| Completed |
NCT00375466 -
Tranexamic Acid, Hemorrhage and Transfusions After Combined Aortic Valve Replacement and Coronary Artery Bypass Surgery.
|
N/A | |
| Completed |
NCT00479362 -
Anticoagulant Therapy During Pacemaker Implantation
|
Phase 4 | |
| Completed |
NCT00147420 -
RCT of Zhi Byed 11 (ZB11) Versus Misoprostol in Tibet
|
N/A | |
| Recruiting |
NCT05945680 -
Tranexamic Acid in Breast Esthetic Surgery.
|
Phase 4 | |
| Completed |
NCT03273322 -
Assessment of Dual Antiplatelet Therapy Versus Rivaroxaban In Atrial Fibrillation Patients Treated With Left Atrial Appendage Closure
|
Phase 2/Phase 3 | |
| Withdrawn |
NCT05672407 -
The Role of Local Tranexamic Acid on Periorbital Oculoplastic Surgery
|
Phase 4 |